Published in

Journal of Otolaryngology - Head & Neck Surgery, 1(52), 2023

DOI: 10.1186/s40463-023-00679-w

Links

Tools

Export citation

Search in Google Scholar

Evaluation of the Effectiveness of Superficial Parotidectomy and Partial Superficial Parotidectomy for Benign Parotid Tumours: A Meta-Analysis

Journal article published in 2023 by Hai-Tao Liu, Wei-Peng Jiang, Gang Xia, Jia-Min Liao
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Objective To quantify the results of superficial parotidectomy (SP) and partial SP (PSP) for benign parotid tumours using a systematic evaluation method. Methods A systematic search of English and Chinese databases (PubMed, Web of Science, Cochrane Library, China Knowledge Network, Wanfang and Vipshop) was conducted to include studies comparing the treatment outcomes of SP with PSP. Results Twenty-three qualified, high-quality studies involving 2844 patients were included in this study. The results of this study showed that compared to the SP surgical approach, the PSP surgical approach reduced the occurrence of temporary facial palsy (OR = 0.33; 95% confidence interval [CI] 0.26–0.41), permanent facial palsy (OR = 0.28; 95% CI 0.16–0.52) and Frey syndrome (OR = 0.36; 95% CI 0.23–0.56) in patients after surgery, and the surgery operative time was reduced by approximately 27.35 min (95% CI − 39.66, − 15.04). However, the effects of PSP versus SP on salivary fistula (OR = 0.70; 95% CI 0.40–1.24), sialocele (OR = 1.48; 95% CI 0.78–2.83), haematoma (OR = 0.34; 95% CI 0.11–1.01) and tumour recurrence rate (OR = 1.41; 95% CI 0.48–4.20) were not statistically significant. Conclusion Compared with SP, PSP has a lower postoperative complication rate and significantly shorter operative time, suggesting that it could be used as an alternative to SP in the treatment of benign parotid tumours with the right indications. Graphical abstract